Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database

被引：0
|
作者：
Michele Fusaroli
Valentina Isgrò
Paola Maria Cutroneo
Carmen Ferrajolo
Valentina Cirillo
Francesca Del Bufalo
Emanuel Raschi
Elisabetta Poluzzi
Gianluca Trifirò
机构：
[1] University of Bologna,Department of Medical and Surgical Sciences, Pharmacology Unit
[2] University of Verona,Department of Diagnostics and Public Health
[3] Sicilian Regional Pharmacovigilance Centre,Department of Pediatric Hematology/Oncology, Cellular and Gene Therapy
[4] University Hospital of Messina,undefined
[5] Regional Centre of Pharmacovigilance and Pharmacoepidemiology,undefined
[6] IRCCS Bambino Gesù Children’s Hospital,undefined
来源：
Drug Safety | 2022年 / 45卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：891 / 908
页数：17
相关论文
共 50 条
  • [1] Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
    Fusaroli, Michele
    Isgro, Valentina
    Cutroneo, Paola Maria
    Ferrajolo, Carmen
    Cirillo, Valentina
    Del Bufalo, Francesca
    Raschi, Emanuel
    Poluzzi, Elisabetta
    Trifiro, Gianluca
    [J]. DRUG SAFETY, 2022, 45 (08) : 891 - 908
  • [2] Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
    Zhao, Dan
    Zhang, Wangxin
    Liu, Yan
    Yan, Zhaojun
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [3] Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database
    Altebainawi, Ali F.
    Alfaraj, Lulwa A.
    Alharbi, Amjad A.
    Alkhuraisi, Fadwa F.
    Alshammari, Thamir M.
    [J]. THERAPEUTIC ADVANCES IN DRUG SAFETY, 2023, 14
  • [4] Neuronal toxicity of monoclonal antibodies (mAbs): an analysis of post-marketing reports from FDA Adverse Event Reporting System (FAERS) safety database
    Kumar, Nitin
    Kalaiselvan, Vivekanandan
    Arora, Mandeep Kumar
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (11) : 1685 - 1695
  • [5] Post-marketing safety of finerenone: a disproportionality analysis of the FDA adverse event reporting system
    Jin, Yiyi
    Fan, Miao
    Zheng, Xiaomeng
    Zhu, Suyan
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
  • [6] Safety of Bempedoic Acid: Post-marketing Analysis of the FDA Adverse Event Reporting System
    Raschi, E.
    Fusaroli, M.
    Forni, M.
    Goldman, A.
    Cicero, A. F. G.
    Poluzzi, E.
    Ponti, F. D.
    [J]. DRUG SAFETY, 2022, 45 (10) : 1287 - 1288
  • [7] Post-marketing safety of checkpoint inhibitors: analysis of the FDA adverse event reporting system
    Elias, Rawad
    Rider, Jennifer
    Rahma, Osama
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [8] Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
    Xiong, Rui
    Lei, Jing
    Pan, Sicen
    Zhang, Hong
    Tong, Yongtao
    Wu, Wei
    Huang, Yi
    Lai, Xiaodan
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [9] Post-marketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA Adverse Event Reporting System (FAERS)
    Zou, Shu-Peng
    Yang, Hai-Yun
    Ouyang, Mengling
    Cheng, Qian
    Shi, Xuan
    Sun, Ming-Hui
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024, 23 (03) : 353 - 362
  • [10] Post-marketing safety concerns with palbociclib: a disproportionality analysis of the FDA adverse event reporting system
    Cheng, Qian
    Shi, Xuan
    Zhao, Yazheng
    Zou, Shupeng
    Sun, Minghui
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024, 23 (05) : 637 - 648
12345